|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shin HR, Carlos MC and Varghese C: Cancer
control in the Asia Pacific region: current status and concerns.
Jpn J Clin Oncol. 42:867–881. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Villanueva A, Newell P, Chiang DY,
Friedman SL and Llovet JM: Genomics and signaling pathways in
hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: from genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sia D and Villanueva A: Signaling pathways
in hepatocellular carcinoma. Oncology. 81:18–23. 2011. View Article : Google Scholar
|
|
8
|
Villanueva A, Chiang DY, Newell P, et al:
Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology. 135:1972–1983. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaminska B, Wesolowska A and Danilkiewicz
M: TGF beta signaling and its role in tumour pathogenesis. Acta
Biochim Pol. 52:329–337. 2005.
|
|
10
|
Inman GJ: Switching TGF-β from a tumor
suppressor to a tumor promoter. Curr Opin Genet Dev. 21:93–99.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Breitkopf K, Weng H and Dooley S:
TGF-β/Smad-signaling in liver cells: Target genes and inhibitors of
two parallel pathways. Signal Transduction. 6:329–337. 2006.
View Article : Google Scholar
|
|
12
|
Achyut BR and Yang L: Transforming growth
factor-β in the gastrointestinal and hepatic tumor
microenvironment. Gastroenterology. 141:1167–1178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fausto N, Campbell JS and Riehle KJ: Liver
regeneration. Hepatology. 43:S45–S53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Itoh S and ten Dijke P: Negative
regulation of TGF-β receptor/Smad signal transduction. Curr Opin
Cell Biol. 19:176–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ellenrieder V: TGFbeta regulated gene
expression by Smads and Sp1/KLF-like transcription factors in
cancer. Anticancer Res. 28:1531–1539. 2008.PubMed/NCBI
|
|
17
|
Kang JS, Liu C and Derynck R: New
regulatory mechanisms of TGF-beta receptor function. Trends Cell
Biol. 19:385–394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moustakas A and Heldin CH: Non-Smad
TGF-beta signals. J Cell Sci. 118:3573–3584. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Subramaniam M, Hawse JR, Rajamannan NM,
Ingle JN and Spelsberg TC: Functional role of KLF10 in multiple
disease processes. Biofactors. 36:8–18. 2010.PubMed/NCBI
|
|
21
|
Spittau B and Krieglstein K: Klf10 and
Klf11 as mediators of TGF-beta superfamily signaling. Cell Tissue
Res. 347:65–72. 2012. View Article : Google Scholar
|
|
22
|
Subramaniam M, Harris SA, Oursler MA,
Rasmussen K and Riggs BL: Identification of a novel
TGF-beta-regulated gene encoding a putative zinc finger protein in
human osteoblasts. Nucleic Acids Res. 23:4907–4912. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cook T, Gebelein B, Belal M, Mesa K and
Urrutia R: Three conserved transcriptional repressor domains are a
defining feature of the TIEG subfamily of Sp1-like zinc finger
proteins. J Biol Chem. 274:29500–29504. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnsen SA, Subramaniam M, Janknecht R and
Spelsberg TC: TGF-beta inducible early geneenhances
TGFbeta/Smad-dependent transcriptional responses. Oncogene.
21:5783–5790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Subramaniam M, Hawse JR, Johnsen SA and
Spelsberg TC: Role of TIEG1 in biological processes and disease
states. J Cell Biochem. 102:539–548. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song KD, Kim DJ, Lee JE, Yun CH and Lee
WK: KLF10, transforming growth factor-β-inducible early gene 1,
acts as a tumor suppressor. Biochem Biophys Res Commun.
419:388–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dooley S, Weng H and Mertens PR:
Hypotheses on the role of transforming growth factor-beta in the
onset and progression of hepatocellular carcinoma. Dig Dis.
27:93–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Buenemann CL, Willy C, Buchmann A,
Schmiechen A and Schwarz M: Transforming growth
factor-beta1-induced Smad signaling, cell-cycle arrest and
apoptosis in hepatoma cells. Carcinogenesis. 22:447–452. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Newell P, Villanueva A, Friedman SL, Koike
K and Llovet JM: Experimental models of hepatocellular carcinoma. J
Hepatol. 48:858–879. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bakiri L and Wagner EF: Mouse models for
liver cancer. Mol Oncol. 7:206–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heldin CH and Miyazono K: Transforming
growth factor-beta. An interesting candidate for clinical use.
Lakartidningen. 92:1569–1572. 1995.(In Swedish). PubMed/NCBI
|
|
32
|
Bensamoun SF, Hawse JR, Subramaniam M, et
al: TGF-beta inducible early gene-1 knockout mice display defects
in bone strength and microarchitecture. Bone. 39:1244–1251. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsubone T, Moran SL, Subramaniam M, Amadio
PC, Spelsberg TC and An KN: Effect of TGF-beta inducible early gene
deficiency on flexor tendon healing. J Orthop Res. 24:569–575.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bos JM, Subramaniam M, Hawse JR, et al:
TGFβ-inducible early gene-1 (TIEG1) mutations in hypertrophic
cardiomyopathy. J Cell Biochem. 113:1896–1903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang L, Lai YK, Zhang JF, et al:
Transactivation of the TIEG1 confers growth inhibition of
transforming growth factor-β-susceptible hepatocellular carcinoma
cells. World J Gastroenterol. 18:2035–2042. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reliene R and Schiestl RH: Antioxidants
suppress lymphoma and increase longevity in Atm-deficient mice. J
Nutr. 137:S229–S232. 2007.
|
|
37
|
Teoh N, Pyakurel P, Dan YY, et al:
Induction of p53 renders ATM-deficient mice refractory to
hepatocarcinogenesis. Gastroenterology. 138:1155–1165. 2010.
View Article : Google Scholar
|
|
38
|
Stracker TH, Roig I, Knobel PA and
Marjanović M: The ATM signaling network in development and disease.
Front Genet. 4:372013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Derynck R and Zhang YE: Smad-dependent and
Smad independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gohla G, Krieglstein K and Spittau B:
Tieg3/Klf11 induces apoptosis in OLI-neu cells and enhances the
TGF-beta signaling pathway by transcriptional repression of Smad7.
J Cell Biochem. 104:850–861. 2008. View Article : Google Scholar : PubMed/NCBI
|
